المؤلفون: Fridley, BL, Goode, EL, Høgdall, E, Jensen, A, Cass, I, Kjær, SK, Johnatty, SE, Nicoletto, MO, D'Andrea, E, Montagna, M, Blanco, I, Lázaro, C, Ma, ESK, Daly, MB, Godwin, AK, Eeles, R, Evans, DG, Frost, D, Peock, S, Hartge, P, Gail, MH, Neuhausen, S, García, MJ, Benítez, J, Sinilnikova, O, Easton, DF, Healey, S, McGuffog, L, Barrowdale, D, Despierre, E, Lambrechts, D, Karlan, BY, Ramus, SJ, Sadetzki, S, Goh, C, ChenevixTrench, G, Bolton, KL, Li, AJ, Walsh, C, Gross, J, Steele, L, Beattie, MS, Chan, S, Nussbaum, RL, Moysich, KB, Leuchter, R, Borg, Å, Olsson, H, Kristoffersson, U, Sieh, W, McGuire, V, Whittemore, AS, Tyrer, J, Song, H, Michie, CO, Gourley, C, Gore, ME, Senter, L, Toland, AE, Glendon, G, HirshYechezkel, G, Lubin, F, Chetrit, A, Mai, PL, Greene, MH, Loud, JT, Levine, DA, Gordon, O, GarciaClosas, M, Gayther, SA, Chanock, SJ, Antoniou, AC, Pharoah, PDP, Andrulis, IL, Kwong, A

مصطلحات موضوعية: endocrine system diseases, skin and connective tissue diseases, female genital diseases and pregnancy complications

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od_______961::26300e4c4ad8b29c56279357f406856d
http://hdl.handle.net/10722/182264

المؤلفون: Hanna D; St. Bartholomew's hospital, Barts Health NHS trust, London, UK. daire.hanna@nhs.net.; Barts Cancer Institute, Queen Mary University, London, UK. daire.hanna@nhs.net., Merrick S; UCLH NHS foundation trust, London, UK., Ghose A; St. Bartholomew's hospital, Barts Health NHS trust, London, UK., Devlin MJ; St. Bartholomew's hospital, Barts Health NHS trust, London, UK., Yang DD; The Royal Marsden NHS foundation trust London and Sutton, London, UK., Phillips E; The Royal Marsden NHS foundation trust London and Sutton, London, UK., Okines A; The Royal Marsden NHS foundation trust London and Sutton, London, UK., Chopra N; The Royal Free, London NHS foundation trust, London, UK., Papadimatraki E; UCLH NHS foundation trust, London, UK., Ross K; Beatson West of Scotland Cancer Centre, Glasgow, UK., Macpherson I; Beatson West of Scotland Cancer Centre, Glasgow, UK., Boh ZY; Edinburgh Cancer Centre and University of Edinburgh, Edinburgh, UK., Michie CO; Edinburgh Cancer Centre and University of Edinburgh, Edinburgh, UK., Swampillai A; Guy's and St Thomas' NHS foundation trust, London, UK., Gupta S; Guy's and St Thomas' NHS foundation trust, London, UK., Robinson T; Bristol Haematology and Oncology Centre- NHS foundation trust, Bristol, UK., Germain L; Leeds Cancer Centre, Leeds, UK., Twelves C; Leeds Cancer Centre, Leeds, UK., Atkinson C; Taunton and Somerset NHS foundation trust, Taunton, UK., Konstantis A; UCLH NHS foundation trust, London, UK.; Princess Alexandra Hospital NHS trust, London, UK., Riddle P; Chelsea and Westminster, London, UK., Cresti N; Northern Centre for Cancer Care, Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle upon Tyne, UK., Naik JD; Harrogate and District NHS foundation trust, Harrogate, UK., Borley A; Velindre Cancer Centre, Cardiff, UK., Guppy A; Mount Vernon Cancer Centre, London, UK., Schmid P; St. Bartholomew's hospital, Barts Health NHS trust, London, UK., Phillips M; St. Bartholomew's hospital, Barts Health NHS trust, London, UK.

المصدر: British journal of cancer [Br J Cancer] 2024 Jun; Vol. 130 (12), pp. 1916-1920. Date of Electronic Publication: 2024 Apr 24.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Triple Negative Breast Neoplasms*/drug therapy , Triple Negative Breast Neoplasms*/pathology , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/adverse effects , Antibodies, Monoclonal, Humanized*/administration & dosage , Camptothecin*/analogs & derivatives , Camptothecin*/therapeutic use , Camptothecin*/adverse effects , Camptothecin*/administration & dosage, Humans ; Middle Aged ; Female ; Aged ; Adult ; United Kingdom/epidemiology ; Retrospective Studies ; Aged, 80 and over ; Neoplasm Metastasis ; Immunoconjugates

المؤلفون: Copson ER; Cancer Sciences Academic Unit, University of Southampton, Southampton, UK. Electronic address: E.Copson@soton.ac.uk., Abraham JE; Precision Breast Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, UK; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Braybrooke JP; University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK., Cameron D; Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK., McIntosh SA; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK., Michie CO; Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK., Okines AFC; The Royal Marsden NHS Foundation Trust, London, UK., Palmieri C; The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK., Raja F; University College London Hospitals NHS Foundation Trust, London, UK; North Middlesex University Hospital, North Middlesex University Hospital NHS Trust, London, UK., Roylance R; University College London Hospitals NHS Foundation Trust, London, UK; NIHR University College London Hospitals Biomedical Research Centre, London, UK., Spensley S; Musgrove Park Hospital, Somerset NHS Foundation Trust, Taunton, UK.

مؤلفون مشاركون: Delphi panellists

المصدر: Breast (Edinburgh, Scotland) [Breast] 2023 Dec; Vol. 72, pp. 103582. Date of Electronic Publication: 2023 Sep 17.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9213011 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-3080 (Electronic) Linking ISSN: 09609776 NLM ISO Abbreviation: Breast Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/pathology, Humans ; Adult ; Female ; Consensus ; Receptor, ErbB-2/metabolism ; Risk Factors ; Risk Assessment ; United Kingdom

المؤلفون: Hollis RL; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK., Meynert AM; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK., Michie CO; Edinburgh Cancer Centre, Western General Hospital, NHS Lothian, Edinburgh, UK., Rye T; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK., Churchman M; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK., Hallas-Potts A; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK., Croy I; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK., McCluggage WG; Department of Pathology, Belfast Health and Social Care Trust, Belfast, UK., Williams ARW; Division of Pathology, The Royal Infirmary of Edinburgh, Edinburgh, UK., Bartos C; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK., Iida Y; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.; The Jikei University School of Medicine, Tokyo, Japan., Okamoto A; The Jikei University School of Medicine, Tokyo, Japan., Dougherty B; Translational Medicine, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Barrett JC; Translational Medicine, Oncology R&D, AstraZeneca, Waltham, Massachusetts., March R; Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, UK., Matakidou A; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Roxburgh P; Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Belfast, UK.; Beatson West of Scotland Cancer Centre, Glasgow, UK., Semple CA; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK., Harkin DP; Almac Diagnostics, Craigavon, UK.; Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK., Kennedy R; Almac Diagnostics, Craigavon, UK.; Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK., Herrington CS; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK., Gourley C; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Aug 15; Vol. 28 (16), pp. 3546-3556.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Cystadenocarcinoma, Serous*/drug therapy , Cystadenocarcinoma, Serous*/genetics , Cystadenocarcinoma, Serous*/pathology , Ovarian Neoplasms*/drug therapy , Ovarian Neoplasms*/genetics , Ovarian Neoplasms*/pathology, Carcinoma, Ovarian Epithelial/genetics ; Female ; Genes, BRCA2 ; Humans ; Neoplasm Grading ; Neoplasm Recurrence, Local/genetics

المؤلفون: Hollis RL; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, Medical Research Council Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom., Churchman M; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, Medical Research Council Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom., Michie CO; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, Medical Research Council Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom., Rye T; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, Medical Research Council Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom., Knight L; Almac Diagnostics, Craigavon, United Kingdom., McCavigan A; Almac Diagnostics, Craigavon, United Kingdom., Perren T; St. James's Institute of Oncology, St. James's University Hospital, Leeds, United Kingdom., Williams ARW; Department of Pathology, University of Edinburgh, Edinburgh, United Kingdom., McCluggage WG; Center for Cancer Research and Cell Biology, Queen's University of Belfast, Belfast, United Kingdom.; Department of Pathology, Belfast Health and Social Care Trust, Belfast, United Kingdom., Kaplan RS; Medical Research Council Clinical Trials Unit at University College London, London, United Kingdom., Jayson GC; Division of Molecular and Clinical Cancer Sciences, University of Manchester, Manchester, United Kingdom., Oza A; Cancer Clinical Research Unit, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada., Harkin DP; Almac Diagnostics, Craigavon, United Kingdom.; Center for Cancer Research and Cell Biology, Queen's University of Belfast, Belfast, United Kingdom., Herrington CS; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, Medical Research Council Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.; Department of Pathology, University of Edinburgh, Edinburgh, United Kingdom.; Division of Pathology, Centre for Comparative Pathology, Cancer Research UK Edinburgh Centre, Medical Research Council Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom., Kennedy R; Almac Diagnostics, Craigavon, United Kingdom.; Center for Cancer Research and Cell Biology, Queen's University of Belfast, Belfast, United Kingdom., Gourley C; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, Medical Research Council Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.

المصدر: Cancer [Cancer] 2019 Aug 15; Vol. 125 (16), pp. 2772-2781. Date of Electronic Publication: 2019 Jun 02.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Cystadenocarcinoma, Serous/*drug therapy , Cystadenocarcinoma, Serous/*mortality , Neoplasm Proteins/*genetics , Nuclear Proteins/*genetics , Ovarian Neoplasms/*drug therapy , Ovarian Neoplasms/*mortality , Repressor Proteins/*genetics, Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; BRCA2 Protein/genetics ; Bevacizumab/administration & dosage ; Carboplatin/administration & dosage ; Cohort Studies ; Computer Simulation ; Cystadenocarcinoma, Serous/genetics ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Middle Aged ; Ovarian Neoplasms/genetics ; Paclitaxel/administration & dosage ; Reproducibility of Results

المؤلفون: Xintaropoulou C; Cancer Research UK Edinburgh Centre and Division of Pathology Laboratory, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK., Ward C; Cancer Research UK Edinburgh Centre and Division of Pathology Laboratory, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK.; The Royal (Dick) School of Veterinary Studies and Roslin Institute, Easter Bush, Roslin, Midlothian, EH25 9RG, UK., Wise A; IOmet Pharma (a wholly owned subsidiary of Merck & Co., Inc., Kenilworth, NJ USA, known as MSD outside the United States and Canada) Nine Edinburgh Bioquarter, Little France Road, Edinburgh, EH16 4UX, UK., Queckborner S; Cancer Research UK Edinburgh Centre and Division of Pathology Laboratory, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK., Turnbull A; Cancer Research UK Edinburgh Centre and Division of Pathology Laboratory, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK., Michie CO; Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK., Williams ARW; Division of Pathology, University of Edinburgh Medical School, 51 Little France Crescent, Edinburgh, EH16 4SA, UK., Rye T; Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK., Gourley C; Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK., Langdon SP; Cancer Research UK Edinburgh Centre and Division of Pathology Laboratory, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK. simon.langdon@ed.ac.uk.

المصدر: BMC cancer [BMC Cancer] 2018 Jun 05; Vol. 18 (1), pp. 636. Date of Electronic Publication: 2018 Jun 05.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*pharmacology , Glycolysis/*drug effects , Ovarian Neoplasms/*enzymology, Carrier Proteins/metabolism ; Cell Line, Tumor ; Female ; Glucose Transporter Type 1/metabolism ; Hexokinase/metabolism ; Humans ; Isoenzymes/metabolism ; L-Lactate Dehydrogenase/metabolism ; Lactate Dehydrogenase 5 ; Membrane Proteins/metabolism ; Thyroid Hormones/metabolism ; Thyroid Hormone-Binding Proteins

المؤلفون: George A; Royal Marsden NHS Foundation Trust, Downs Road, London SM2 5PT, UK., Kristeleit R; Royal Marsden NHS Foundation Trust, Downs Road, London SM2 5PT, UK., Rafii S; Royal Marsden NHS Foundation Trust, Downs Road, London SM2 5PT, UK., Michie CO; Royal Marsden NHS Foundation Trust, Downs Road, London SM2 5PT, UK., Bowen R; Royal Marsden NHS Foundation Trust, Downs Road, London SM2 5PT, UK., Michalarea V; Royal Marsden NHS Foundation Trust, Downs Road, London SM2 5PT, UK., van Hagen T; Royal Marsden NHS Foundation Trust, Downs Road, London SM2 5PT, UK., Wong M; Royal Marsden NHS Foundation Trust, Downs Road, London SM2 5PT, UK., Rallis G; Royal Marsden NHS Foundation Trust, Downs Road, London SM2 5PT, UK., Molife LR; Royal Marsden NHS Foundation Trust, Downs Road, London SM2 5PT, UK., Lopez J; Royal Marsden NHS Foundation Trust, Downs Road, London SM2 5PT, UK., Banerji U; Royal Marsden NHS Foundation Trust, Downs Road, London SM2 5PT, UK; The Institute of Cancer Research, Cotswold Road, London SM2 5NG, UK., Banerjee SN; Royal Marsden NHS Foundation Trust, Downs Road, London SM2 5PT, UK., Gore ME; Royal Marsden NHS Foundation Trust, Downs Road, London SM2 5PT, UK., de Bono JS; Royal Marsden NHS Foundation Trust, Downs Road, London SM2 5PT, UK; The Institute of Cancer Research, Cotswold Road, London SM2 5NG, UK., Kaye SB; Royal Marsden NHS Foundation Trust, Downs Road, London SM2 5PT, UK., Yap TA; Royal Marsden NHS Foundation Trust, Downs Road, London SM2 5PT, UK; The Institute of Cancer Research, Cotswold Road, London SM2 5NG, UK. Electronic address: timothy.yap@icr.ac.uk.

المصدر: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2017 May; Vol. 76, pp. 52-59. Date of Electronic Publication: 2017 Mar 06.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Clinical Trials, Phase I as Topic*, Adenocarcinoma, Clear Cell/*drug therapy , Antineoplastic Agents/*therapeutic use , Carcinoma, Endometrioid/*drug therapy , Carcinosarcoma/*drug therapy , Granulosa Cell Tumor/*drug therapy , Neoplasms, Cystic, Mucinous, and Serous/*drug therapy , Ovarian Neoplasms/*drug therapy, Adenocarcinoma, Clear Cell/genetics ; Adenocarcinoma, Clear Cell/metabolism ; Adenocarcinoma, Clear Cell/pathology ; Adult ; Aged ; CA-125 Antigen/metabolism ; Carcinoma, Endometrioid/genetics ; Carcinoma, Endometrioid/metabolism ; Carcinoma, Endometrioid/pathology ; Carcinosarcoma/genetics ; Carcinosarcoma/metabolism ; Carcinosarcoma/pathology ; Drug Discovery ; England ; Female ; Genes, BRCA1 ; Genes, BRCA2 ; Granulosa Cell Tumor/genetics ; Granulosa Cell Tumor/metabolism ; Granulosa Cell Tumor/pathology ; Hemoglobins/metabolism ; Hereditary Breast and Ovarian Cancer Syndrome/genetics ; Humans ; Leukocyte Count ; Membrane Proteins/metabolism ; Middle Aged ; Neoplasm Metastasis ; Neoplasms, Cystic, Mucinous, and Serous/genetics ; Neoplasms, Cystic, Mucinous, and Serous/metabolism ; Neoplasms, Cystic, Mucinous, and Serous/pathology ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/metabolism ; Ovarian Neoplasms/pathology ; Prognosis ; Retrospective Studies ; Serum Albumin/metabolism ; Severity of Illness Index ; Survival Rate ; Treatment Outcome

المؤلفون: Evans A; Dundee Cancer Centre, Ninewells Hospital & Medical School, Mailbox 4, Dundee, DD1 9SY, UK, a.z.evans@dundee.ac.uk., Rauchhaus P, Whelehan P, Thomson K, Purdie CA, Jordan LB, Michie CO, Thompson A, Vinnicombe S

المصدر: Breast cancer research and treatment [Breast Cancer Res Treat] 2014 Jan; Vol. 143 (1), pp. 153-7. Date of Electronic Publication: 2013 Dec 04.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE

مواضيع طبية MeSH: Axilla* , Elasticity Imaging Techniques*, Breast Neoplasms/*diagnostic imaging , Breast Neoplasms/*pathology , Lymph Nodes/*pathology, Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Lymphatic Metastasis ; Middle Aged ; Neoplasm Grading ; Prognosis ; Risk Factors

المؤلفون: Gray TA; p53 Signal Transduction Group, Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XR, Scotland, UK., MacLaine NJ, Michie CO, Bouchalova P, Murray E, Howie J, Hrstka R, Maslon MM, Nenutil R, Vojtesek B, Langdon S, Hayward L, Gourley C, Hupp TR

المصدر: Journal of immunological methods [J Immunol Methods] 2012 Apr 30; Vol. 378 (1-2), pp. 20-32. Date of Electronic Publication: 2012 Feb 15.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 1305440 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7905 (Electronic) Linking ISSN: 00221759 NLM ISO Abbreviation: J Immunol Methods Subsets: MEDLINE

مواضيع طبية MeSH: Biomarkers, Tumor/*genetics , Biomarkers, Tumor/*metabolism , Carrier Proteins/*genetics , Carrier Proteins/*metabolism , Cisplatin/*pharmacology , Neoplasm Proteins/*genetics , Neoplasm Proteins/*metabolism , Ovarian Neoplasms/*drug therapy , Ovarian Neoplasms/*metabolism, Amino Acid Sequence ; Animals ; Antineoplastic Agents/pharmacology ; Cell Line, Tumor ; Drug Resistance, Neoplasm ; Epitope Mapping/methods ; Female ; Humans ; Mice ; Mice, Nude ; Molecular Sequence Data ; Mucoproteins ; Oncogene Proteins ; Ovarian Neoplasms/genetics ; Proteins/genetics ; Proteins/metabolism ; Receptors, Estrogen/genetics ; Receptors, Estrogen/metabolism ; Transfection/methods ; Xenograft Model Antitumor Assays

المؤلفون: Bolton KL; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA., Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, Lambrechts D, Despierre E, Barrowdale D, McGuffog L, Healey S, Easton DF, Sinilnikova O, Benítez J, García MJ, Neuhausen S, Gail MH, Hartge P, Peock S, Frost D, Evans DG, Eeles R, Godwin AK, Daly MB, Kwong A, Ma ES, Lázaro C, Blanco I, Montagna M, D'Andrea E, Nicoletto MO, Johnatty SE, Kjær SK, Jensen A, Høgdall E, Goode EL, Fridley BL, Loud JT, Greene MH, Mai PL, Chetrit A, Lubin F, Hirsh-Yechezkel G, Glendon G, Andrulis IL, Toland AE, Senter L, Gore ME, Gourley C, Michie CO, Song H, Tyrer J, Whittemore AS, McGuire V, Sieh W, Kristoffersson U, Olsson H, Borg Å, Levine DA, Steele L, Beattie MS, Chan S, Nussbaum RL, Moysich KB, Gross J, Cass I, Walsh C, Li AJ, Leuchter R, Gordon O, Garcia-Closas M, Gayther SA, Chanock SJ, Antoniou AC, Pharoah PD

مؤلفون مشاركون: EMBRACE, kConFab Investigators, Cancer Genome Atlas Research Network

المصدر: JAMA [JAMA] 2012 Jan 25; Vol. 307 (4), pp. 382-90.

نوع المنشور: Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 7501160 Publication Model: Print Cited Medium: Internet ISSN: 1538-3598 (Electronic) Linking ISSN: 00987484 NLM ISO Abbreviation: JAMA Subsets: MEDLINE

مواضيع طبية MeSH: Genes, BRCA1* , Genes, BRCA2* , Germ-Line Mutation*, Ovarian Neoplasms/*genetics , Ovarian Neoplasms/*mortality, Adult ; Aged ; Female ; Humans ; Middle Aged ; Prognosis ; Survival Analysis